miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn's disease

Area of Science:

• Molecular Biology
• Gastroenterology
• Immunology

Background:

• Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) with complex genetic and environmental causes.
• MicroRNA-122 (miR-122) deregulation is observed in CD, but its precise role and molecular targets are not fully understood.
• Nucleotide-binding oligomerization domain 2 (NOD2/CARD15) is a key gene associated with CD susceptibility.

Purpose of the Study:

• To investigate the molecular mechanisms linking miR-122 and NOD2 in the context of CD.
• To determine the role of the miR-122/NOD2 interaction in regulating intestinal epithelial cell responses to lipopolysaccharide (LPS).

Main Methods:

• Identification of NOD2 as a functional target of miR-122 in HT-29 cells.
• Assessment of miR-122's effect on LPS-induced apoptosis and NOD2 expression.
• Analysis of nuclear factor κB (NF-κB) activation and pro-inflammatory cytokine expression (TNF-α, IFN-γ) and anti-inflammatory cytokines (IL-4, IL-10).

Main Results:

• MiR-122 inhibited LPS-induced apoptosis by suppressing NOD2 expression in HT-29 cells.
• NOD2 interaction with LPS, leading to NF-κB activation, was inhibited by miR-122 precursor or NOD2 shRNA.
• Pretreatment with miR-122 precursor, NOD2 shRNA, or an NF-κB inhibitor reduced pro-inflammatory cytokines and increased anti-inflammatory cytokines.

Conclusions:

• MiR-122 targets NOD2, playing a protective role against LPS-induced intestinal epithelial cell injury.
• The miR-122/NOD2 pathway modulates NF-κB signaling and cytokine balance, impacting inflammatory responses.
• These findings highlight miR-122 and NOD2 as potential therapeutic targets for Crohn's disease and related IBD.